NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EnginZyme

EnginZyme

Private
SolnaFrontier & Industrial Techhttps://enginzyme.com/

Last Round

Series B

Dec 19, 2022

Total Funding Raised

$38.14M

Company Overview

EnginZyme is a biotechnology company that develops cell-free synthetic technology to enable sustainable biomanufacturing for the chemical industry.

Sector

Frontier & Industrial Tech

Verticals

Biotechnology, Clean Manufacturing, Sustainable Materials

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

biomanufacturingbiocatalysisenzyme immobilizationcell-free synthesisprotein designsynbiogenerative AIindustrial biotechnologysustainable chemistrygreen chemistryprocess developmentEziGin-silico designbiotech R&Dprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EnginZyme Comparables

Compare EnginZyme with similar companies based on industry and business-model similarity.

EnginZyme comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zymtronix
83%
FabricNano
83%
Enzymicals AG
80%

EnginZyme Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 19, 2022
Series A ExtensionFeb 11, 2021
Series AApr 21, 2020
GrantJan 1, 2020

Key People

Founding team and executive leadership

de Gantes Aymeric

Chief Executive Officer

Executive Team

Marco Antonio Saucedo

Chief Technology Officer

Executive Team

EnginZyme Investors

Notable investors and investment history

EnginZyme investors
InvestorRounds
Bunge VenturesSeries B
SEB GroupSeries A Extension, Series B
Navigare VenturesSeries B
Almi Invest ABSeries B
IndustrifondenSeries B, Series A Extension
European Union's Horizon 2020 research and innovation programme (Marie Skłodowska-Curie)Grant
Sofinnova PartnersSeries A Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2025

    Aymeric de Gantès appointed as the new Chief Executive Officer.

  • Dec 19, 2022

    $22M round with participation from Bunge Ventures and SEB Group.

EnginZyme Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EnginZyme Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EnginZyme's valuation, stock price, and market status.

Firmographic Details

HeadquartersSolna
Employee Range35
Year Founded2014
Last FundingDec 19, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.